Calliditas Therapeutics raise US$90m in Nasdaq IPO
Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Entries by Thomas Gabrielczyk
Hyloris Pharmaceuticals prepared to go public
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
ELEVECTA® Unlocking The Full Potential of Gene Therapy
Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.
New algorithm predicts rheumatoid arthritis
Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
Novo Holdings invests into AI CRO ExScientia
Poxel SA raises €17.7m through capital increase
Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.
Study might prepare for rapid revision of EU GMO law
The European Commission has taken up the European Council’s demand for deregulation of new plant breeding techniques (NBT). A new study is being conducted to form the basis for a campaign from the Commission to inform the public about the benefits of targeted mutation technologies and to break the resistance to genetically engineered crops.
British scientists start Phase II on COVID-19 vaccine
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.